Gentium S.p.A. Appoints Swedish Orphan Biovitrum as Exclusive Distributor of Defibrotide in Nordic and Baltic Territories

VILLA GUARDIA (COMO), Italy, Jan. 9, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) announced the appointment of the Swedish Orphan Biovitrum A.B., (Sobi) (Stockholm:SOBI) as the exclusive distributor of Defibrotide in the following territories: Sweden, Denmark, Norway, Iceland, Finland, Latvia, Lithuania and Estonia. Under the terms of the agreement, which is valid for 10 years, Sobi will be responsible for managing named-patient requests and achieving price and reimbursement approvals in these territories. Following regulatory approval to market Defibrotide, if any, Sobi will be responsible for sales, marketing and local medical affairs activities in the territories.

Back to news